Considerations for the selection of disease-modifying treatments in SMA:  A case-based discussion episode artwork

EPISODE · Apr 27, 2022 · 36 MIN

Considerations for the selection of disease-modifying treatments in SMA: A case-based discussion

from touchPODCAST · host touchpodcast

touchPANEL DISCUSSION for touchNEUROLOGY Listen as three experts in spinal muscular atrophy (SMA) discuss factors influencing treatment decision-making with approved SMA therapies using patient case studies. The experts Prof. Eugenio Mercuri – Policlinico Universitario Agostino Gemelli, Rome, Italy Prof. Nathalie Goemans – UZ Leuven, Leuven, Belgium Prof. Dr. med. Tim Hagenacker – Essen University Hospital, Essen, Germany This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from Biogen and Novartis Gene Therapies. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchneurology.com/cme/selecting-disease-modifying-treatments-in-sma/

Episode metadata supplied by the publisher feed · Published Apr 27, 2022

Embed this episode

Ready to play

Considerations for the selection of disease-modifying treatments in SMA: A case-based discussion

0:00 36:57

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 36 minutes long.

When was this touchPODCAST episode published?

This episode was published on April 27, 2022.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!